BOC Sciences at World Vaccine Congress Europe 2023

We are pleased to announce that BOC Sciences will be attending the World Vaccine Congress Europe 2023, October 16-19 in Barcelona, Spain.

• Our display space is #80.

For more information about BOC Sciences' participation in World Vaccine Congress Europe, please visit event page.

The World Vaccine Congress Europe is the premier event for vaccine research and development in Europe. It comprehensively covers the entire vaccine development journey from clinical trials to market access, and is known as the largest and most respected vaccine conference in the world. The World Vaccine Congress Europe brings together experts from all areas of the industry, including Clinical Development, Bioprocessing & Manufacturing, Cancer Immunotherapy, Respiratory & Infectious Diseases, Immunoassays, Vaccine Safety, Vaccine Collaboration, Same Health, Vaccine Supply & Logistics, Biodefense, and Anti-microbial Drug Resistance. If you are involved in vaccine research or unfamiliar with vaccines due to a pandemic, then this is the most important conference you will attend.

Small nucleic acid drugs (oligonucleotide sequences less than 30 nt in length), small molecule nucleoside analogs and mRNA vaccines are nucleotide-based drugs or vaccines. They achieve therapeutic effects by binding to the RNA of the target molecule and inhibiting its translation or regulation. mRNA vaccines are a new type of vaccine that stimulates an immune response by injecting the mRNA produced in the body to encode antigenic proteins of the pathogen. With the emergence of mRNA vaccines, the development of oligonucleotide drugs has entered a new phase. mRNA vaccines utilize the excellent properties of oligonucleotides to induce immune responses by delivering mRNA molecules encoding antigens, and have become an important tool for dealing with infectious diseases such as COVID-19.

The focus of mRNA vaccine development needs to address the delivery technology, where naked RNA is susceptible to attack by RNA-cleaving enzymes in vivo. The in vivo behavior of mRNA delivery is highly dependent on the material used, i.e., using the same material, the particle size, structural features, and surface properties of the lipid nanoparticles that are formed by complexing/encapsulation with nucleic acids have a significant impact on the in vivo behavior.

BOC Sciences has developed a variety of drug delivery platforms including lipid nanoparticles, liposomes, polymer complexes, cationic peptides and others. Lipid nanoparticles (LNPs) are currently the mainstream delivery vehicle and can be a good solution to the problems in mRNA delivery. Lipid nanoparticles are nanoscale particles composed of lipids, which have unique advantages in delivering mRNA. Firstly, LNP is spherical particles that can encapsulate mRNA and resist the action of nuclease. Secondly, LNP composition is similar to the cell membrane, which is easy to fuse with the recipient cells and has high transfection efficiency, and it is not limited by the host, and it can deliver mRNAs of different size fragments.

BOC Sciences' combined strengths, capabilities, and growing laboratory capacity provide comprehensive services to all clients. Our combined expertise in drug delivery platform development will accelerate therapeutic and vaccine development. We look forward to connecting with you at this prestigious event and sharing insights into our cutting-edge products and services. Our team of experts will be on hand to answer your questions and discuss the latest advances in vaccine development.

Our Capabilities

• Customized mRNA
• Development of different drug delivery platform systems
• Upstream and downstream process development including quality control
• R&D capabilities backed by a 5,500m² multifunctional laboratory